New dosing strategy aims to make liver cancer drug easier to tolerate

NCT ID NCT05622136

Ongoing Disease control Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to see how many can complete four treatment cycles, while also tracking side effects, quality of life, and cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Regorafenib (a targeted cancer drug taken as pills)
What this could lead to: If successful, this could offer a better-tolerated way to give regorafenib, helping more patients complete treatment and potentially control their liver cancer longer.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drug can still cause side effects, and it is not a cure—cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER CANCER

Contacts and locations

Locations

ICESP - Instituto do Câncer do Estado de São Paulo

São Paulo, São Paulo, 01246-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.